UPDATE 1-Cubist mid-stage safety trial on Cubicin meets goals

* Drug studied in treatment of prosthetic joint infections

* Drug studied at doses of 6 and 8 mg/kg

July 13 (BestGrowthStock) – Cubist Pharmaceuticals Inc (CBST.O: )
said a mid-stage safety study on Cubicin, its lead antibiotic
injection, has met its goals in the treatment of prosthetic
joint infections caused by certain gram positive pathogens.

The trial studied anti-infective therapy during two-stage
surgery for the replacement of infected prosthetic hip or knee
joints.

The study compared Cubicin at doses of 6 and 8 mg/kg with
certain standard-of-care antibiotics administered for about six
weeks following surgery to remove the infected prosthesis.

The primary goal of the mid-stage study was to assess the
safety and tolerability of Cubicin at the two doses.

Cubicin is approved in the United States as an antibiotic
injection to treat bacterial infections, and contributes about
95 percent of the company’s revenue.

Shares of Cubicin were up 1 percent at $22.02 in after
market trade. They closed at $21.88 Tuesday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Don
Sebastian)

UPDATE 1-Cubist mid-stage safety trial on Cubicin meets goals